From all of us at Curevo, we wish all those travelling this week to see family and friends safe and smooth travels!

90% of adults over 50 already carry the virus causing shingles. Over 30% of these will develop shingles in their lifetime. For most older adults, the shingles rash lasting 2-4 weeks is bad enough, but 10-18% develop serious, long-lasting, and often debilitating nerve pain.

Despite an available vaccine for older adults, an estimated 1,000,000 older adults in the US get shingles each year and cases are rising steadily. Lack of awareness is a big part, but side effects and variability of supply of the current vaccine contribute as well.

Post-herpetic neuralgia (PHN) is a lasting neurological condition suffered by 10-18% of the estimated 1,000,000 US adults who get shingles each year. Often described as a burning, stabbing, or gnawing pain, it can be very debilitating. There is no effective treatment for PHN.

Post-herpetic neuralgia (PHN) is a lasting neurological condition suffered by 10-18% of the estimated 1,000,000 US adults who get shingles each year. Often described as a burning, stabbing, or gnawing pain, it can be very debilitating. There is no effective treatment for PHN.

Due to heightened clot formation, contracting shingles has been associated with a significant increase in the risk of stroke and heart attack. The risk may persist a year or more and those under 40 may be at greater risk. Vaccination is proven to reduce the risk of Shingles.

Our CRV-101 is a clinical-stage subunit vaccine under investigation for preventing shingles in older adults. Our Phase 1 study demonstrated CRV-101’s favorable tolerability profile. If approved, we hope this will encourage more people to be vaccinated against shingles.

From our family at Curevo, to all those celebrating holidays over the coming weeks, we hope you have a joyous time enjoying the company of friends and family. Peace on earth and good will to all humankind.

Our CRV-101 clinical-stage subunit vaccine against shingles enjoys a highly scalable, straightforward manufacturing profile. One of the barriers to seeing more older adults vaccinated against shingles are supply issues, which we hope to address if CRV-101 is approved.

Happy New Year to All! #2023

Curevo is looking forward to catching up with all our friends and colleagues at #JPM23 next week!

Happy #InternationalWomensDay! We are so proud and honored to be working alongside these truly inspiring women. Cheers to all and many more who are not pictured. You are all amazing! #biotech #womeninbiotech #IWD2023 #curevocareers

The team at Curevo welcomes Dr. Guy De La Rosa as our Chief Medical Officer. curevovaccine.com/uncategorized/…

🌍 The Curevo Team will be attending the World Vaccine Congress in Barcelona. If you are in the area and would like to meet with us, we have a limited number of FREE tickets to share with you. You can register today by following this link: i.snoball.it/p/4a9g/i

It's a big event in any biotech's life to present at the JPM conference -- even more so when you're one of the handful of private companies selected. On January 10, at 4pm. Please join us in the Golden Gate room for our #JPM24 debut! globenewswire.com/news-release/2…

Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix®. Phase 3 trial to begin 2024. #JPM24 curevovaccine.com/uncategorized/…

In one hour, our CEO will be presenting positive Phase 2 data from our randomized trial of amezosvatein, a next-generation vaccine for shingles, in the Golden Gate room, 32nd floor, here at #JPM24

Enjoying #SoundersMatchday with some of the Curevo Vaccine team!

Supporting a great cause at St. Jude Run/Walk